Riad Dirani | Riad Dirani, Vice President, Global Health Economics and Outcomes Research
Teva Pharmaceuticals

Riad Dirani, Riad Dirani, Vice President, Global Health Economics and Outcomes Research, Teva Pharmaceuticals

Riad Dirani, PhD, is currently the VP of Global Health Economic and Outcomes Research at Teva Pharmaceuticals. His responsibilities include overseeing the establishment of this function within Medical Affairs, and developing the strategic capabilities for HEOR to optimize the development and commercialization of Teva’s portfolio of products and offerings globally.
 
Riad has worked in the pharmaceutical industry since 2000, including positions of increasing responsibility at Aventis, GlaxoSmithKline, Pfizer, and Johnson & Johnson in multiple therapeutic areas. Riad joined Teva in 2014 to build the global HEOR group and establish its operating model. 
 
Riad received his Ph.D. in Health Services Research/Health Economics from The Pennsylvania State University. He has published over 25 journal articles and made numerous presentations to professional organizations, including the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and therapeutic-specific conferences.

Appearances:



Pharma Pricing & Market Access USA Day 1 @ 12:50

ROUND TABLES

1) US payer introduction to the structures and processes

  • Jennifer L. Bragg, Partner, FDA regulatory and litigation attorney
  • Asif Velani, Head of Market Access, Puma Biotechnology
2) Statistical methodologies- learning new meta analysis techniques
  • Andy Gunn, Global Head Evidence Generation, UCB BioPharmaceuticals Inc
  • Simon Semus, Observational Data Analyst, GSK
3) Policy framework- Patient data and evidence management
  • Amy Niles, Vice President, External Affairs, Patient Access Network Foundation
  • Leena Patel, President and CEO, PAN Foundation
4) Economic Evaluation of Vaccines- Providing value through the prevention of disease
  • David Davidovic, Former Vice President & Global Head, Commercial Services, Roche & Genentech
5) Value Frameworks - What is the future?
  • Christine Verini, Chief Business Development Officer, CancerCare
  • John Stoeckle, Physician, Thomas Jefferson University Hospitals, Inc
  • Susan Gabriel, Director, Global Health Economics and Outcomes Research, Teva Pharmaceuticals
6) Biosimilars - Market Access
  • Jennifer Voelker, HEOR fellow, Janssen
  • Sonia Lee, HEOR fellow, Ethicon
  • Ravi Iyer, Director Global Health Economics and Reimbursement, Teva
  • Ying Wu, Director HEOR, Teva
  • Ravi Iyer, Director Global Health Economics and Reimbursement, Teva
7) BioBetter Pricing Models- Discovering how biobetters are becoming mainstream
  • Boxiong Tang, Sr. Director, GHEOR, Teva
  • Riad Dirani, Vice President Global Health Economics & Outcomes Research & EBM Global Medical Affairs, Teva Pharmaceuticals
8) Dynamic Drug Pricing Frameworks- Converging supply and demand Uber style
  • Ben Locwin, Ex-Executive Director, Roche
9) EHR records- How to bennefit 
  • Yong Chen, Director of Real World Data & Analytics, GSK
10) Post Release Commercialization - When and how
  • Shailesh Chavan, Vice President, Clinical Research, Drug Safety & Medical Affairs, Biotest Pharmaceuticals

 

BioBetter Pricing Models- Discovering how biobetters are becoming mainstream

back to speakers